Cosmos Health Reports Record Q2 Revenue and Expanding Manufacturing Backlog
核心洞察
Cosmos Health (搜索) (NASDAQ: COSM) reported record second-quarter 2026 revenue of $18.99 million, up 28.8% year over year, with first-half revenue rising 29.7% to $36.91 million.
Adjusted gross profit increased 58.4% to $1.84 million, while adjusted gross margin expanded 165 basis points to 9.54%, reflecting a shift toward higher-margin proprietary products.
Cana Laboratories (搜索)' contract manufacturing orderbook reached an all-time high exceeding 25 million units across nine therapeutic categories, with agreements extending up to ten years.
Cosmos Health (搜索) (NASDAQ: COSM) delivered a strong second-quarter update that provides additional evidence the company is transitioning from a collection of healthcare assets into a larger, vertically integrated healthcare platform with increasingly meaningful scale. Second-quarter revenue reached a record $18.99 million, up 28.8% from $14.75 million a year ago, while first-half revenue increased 29.7% to $36.91 million from $28.46 million. Adjusting for certain sales discount reversals, Q2 revenue was $19.32 million, up 31%, and first-half adjusted revenue reached $37.72 million, up 32.5% — representing an adjusted annualized revenue run rate exceeding $75 million.
The quality of the Q2 growth also appears to be improving. Reported gross profit increased 29.9% to $1.51 million, roughly matching revenue growth. More impressively, adjusted gross profit increased 58.4% to $1.84 million, while adjusted gross margin expanded 165 basis points to 9.54%. This margin expansion is particularly significant because Cosmos has historically generated a substantial portion of revenue from relatively low-margin pharmaceutical distribution; as higher-margin proprietary products, contract manufacturing, and specialized healthcare products become larger contributors, gross profit has the opportunity to grow materially faster than revenue.
Operating Leverage and Financial Position
Operating expenses increased 16.5% to $4.44 million while revenue grew 28.8%, and salaries and wages actually declined 0.7% year over year despite the substantial increase in revenue. Management also reported that receivables and inventory declined even as sales approached 30% growth, with first-half inventory down 21.8%. The Q2 adjusted EBITDA loss improved to $1.13 million from a loss of $1.31 million a year earlier despite continued investment in international expansion and proprietary brands.
The reported net loss of $6.09 million appears much less favorable compared with a $2.83 million loss a year ago. However, approximately $2.65 million of the quarterly loss reflected non-cash charges, principally fair-value adjustments associated with financing arrangements rather than core operations.
The balance sheet also showed meaningful progress. Total liabilities declined $6.27 million, or 13.3%, from year-end to $40.79 million, while stockholders' equity increased $2.25 million, or 12.2%, to $20.67 million. The liabilities-to-assets ratio improved by 550 basis points, from 71.9% to 66.4%. Cosmos reported $4.15 million of liquid assets consisting of cash, marketable securities, and digital assets.
CosmoFarm and Cana Laboratories Drive Growth
Within the COSM universe, CosmoFarm (搜索) continues to be one of the largest drivers of growth. The business generated more than $15 million of quarterly revenue during Q2, equivalent to an annualized run rate exceeding $60 million, while adding more than 75 pharmacies to its distribution network. Cosmos is also investing in robotic automation and AI technology at CosmoFarm, which management believes could reduce certain operating expenses by as much as 30%.
Cana Laboratories (搜索) may ultimately prove even more important from a profitability standpoint. Its contract manufacturing orderbook has reached an all-time high exceeding 25 million units across nine therapeutic categories, with agreements extending for periods of up to ten years. Recent agreements include a 3.9-million-unit contract with Verisfield (搜索) for VASCLOR GEST (搜索) progesterone pessaries and a 2.86-million-unit agreement with Pharmex (搜索) covering three dermatological products. Additional orders from Nassington and Verisfield totaled more than 253,000 units, while Cosmos inaugurated a new capsule manufacturing line accompanied by a five-year agreement with Provident Pharmaceuticals (搜索) for 385,000 units of CERTORUN (搜索).
Additionally, Cana entered an advisory agreement with the European Investment Bank (搜索) regarding potential financing of Cosmos' R&D program, with EIB financing potentially totaling as much as €25 million.
Proprietary Products and U.S. Expansion
Cosmos continues to expand its higher-margin proprietary brands internationally. Sky Premium Life (搜索) achieved pan-European distribution through Skroutz, making its products available across all 27 EU member states. The company also signed a distribution agreement with International Medical Company in Qatar, including an initial order for 31,000 Sky Premium Life units, and received another 60,000-unit order from Pharmalink in the UAE, bringing cumulative orders from that relationship to 270,000 units.
C-Scrub (搜索) and C-Sept (搜索) are also becoming increasingly meaningful, with combined annualized sales exceeding $1.5 million in Greece and the UK. Cosmos believes planned European expansion could ultimately generate approximately $7.4 million in revenue and $5.3 million in gross profit. C-Scrub Wash 4% successfully completed EN 12791 testing, the European standard covering surgical hand disinfection, potentially opening hospital, surgical, and professional healthcare markets. Separately, successful EN 1656 and EN 1657 testing has allowed Cosmos to target the approximately $69 billion global animal-health market with a veterinary formulation of C-Scrub Wash 4%.
During Q2, Cosmos moved its "18 Series" from concept toward commercialization. The platform is intended to eventually contain 18 clinically validated nutraceutical products addressing areas including liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging. Cosmos also entered the global skincare market, which the company estimates at approximately $163 billion, with U.S. sales already underway.
Share Repurchases and Outlook
Management authorized a share repurchase program of up to $5 million in June. It repurchased 2.65 million shares for approximately $513,000 during Q2, and purchases continued during Q3. As of the announcement, Cosmos had repurchased approximately 5.112 million shares for roughly $1.11 million. At the same time, approximately 4.87 million Series B warrants expired unexercised during the quarter, eliminating roughly 38% of the company's warrant overhang without additional dilution.
The most compelling element of the COSM story is the changing composition of the business. Cosmos increasingly combines the scale of pharmaceutical distribution, the recurring potential of contract manufacturing, the higher margins of proprietary healthcare products, international expansion, U.S. nutraceutical opportunities and an emerging R&D portfolio. Q2 2026 provides evidence that this strategy is gaining traction, with revenue increasing nearly 29%, adjusted gross profit up 58%, adjusted gross margin expanding 165 basis points, operating expenses growing considerably more slowly than revenue, adjusted EBITDA improving, liabilities declining 13%, and equity increasing 12%.